Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Effects of long-term nutrient additions on Arctic tundra, stream, and lake ecosystems: beyond NPP.

Gough L, Bettez ND, Slavik KA, Bowden WB, Giblin AE, Kling GW, Laundre JA, Shaver GR.

Oecologia. 2016 Nov;182(3):653-65. doi: 10.1007/s00442-016-3716-0. Epub 2016 Aug 31. Review.

PMID:
27582122
2.

High-Dose Abciximab During Coronary Angioplasty in a Patient with Essential Thrombocytosis.

Kohl DW, Slavik KJ, Kamath G, Lehr JM, McDonald MJ, Rubio F.

J Invasive Cardiol. 1998 Apr;10(3):173-176. No abstract available.

PMID:
10762789
3.

A carboxy-terminal peptide of the alpha 1-subunit of the dihydropyridine receptor inhibits Ca(2+)-release channels.

Slavik KJ, Wang JP, Aghdasi B, Zhang JZ, Mandel F, Malouf N, Hamilton SL.

Am J Physiol. 1997 May;272(5 Pt 1):C1475-81.

PMID:
9176137
4.

Interaction between ryanodine and neomycin binding sites on Ca2+ release channel from skeletal muscle sarcoplasmic reticulum.

Wang JP, Needleman DH, Seryshev AB, Aghdasi B, Slavik KJ, Liu SQ, Pedersen SE, Hamilton SL.

J Biol Chem. 1996 Apr 5;271(14):8387-93.

5.

Loss of adenosine-induced negative inotropic effect in hyperexcited rabbit hearts: relationship to PKC.

Cano C, Slavik KJ, Malik KU.

Am J Physiol. 1995 Mar;268(3 Pt 2):H1037-44.

PMID:
7535002
6.

Localization of the high and low affinity [3H]ryanodine binding sites on the skeletal muscle Ca2+ release channel.

Callaway C, Seryshev A, Wang JP, Slavik KJ, Needleman DH, Cantu C 3rd, Wu Y, Jayaraman T, Marks AR, Hamilton SL.

J Biol Chem. 1994 Jun 3;269(22):15876-84.

7.

Naloxone-induced potentiation of cardiac alpha-2 adrenoceptor-mediated depression of neurogenic tachycardia.

Slavik KJ, Szilagyi JE.

J Pharmacol Exp Ther. 1993 Jul;266(1):184-91.

PMID:
8101216
8.

Involvement of inhibitory dopamine-2 receptors in resting bradycardia in exercise-conditioned rats.

Slavik KJ, LaPointe J.

J Appl Physiol (1985). 1993 May;74(5):2086-91.

PMID:
8101519
10.

A method for maintaining and protecting chronic arterial and venous catheters in conscious rats.

Kurowski SZ, Slavik KJ, Szilagyi JE.

J Pharmacol Methods. 1991 Dec;26(4):249-56.

PMID:
1758191
11.

Organ distribution of fibrinogen-bound methotrexate in mice with Gardner lymphosarcoma.

Slavíková V, Dyr JE, Motycka K, Pristoupilová K, Holý P, Slavík K.

Neoplasma. 1987;34(3):269-76.

PMID:
3614463
14.

The effect of fibrinogen-methotrexate derivatives on HeLa cell growth.

Dyr JE, Hermanová E, Slavík K, Vodrázka Z.

Neoplasma. 1986;33(4):401-7.

PMID:
3531894
16.

LDH-viral activity transferred with cell surface antigens of Gardner lymphosarcoma cells. Short communication.

Motycka K, Bostík J, Slavík K, Bures L, Pezlarová J, Jandová A.

Z Versuchstierkd. 1984;26(5):209-10. No abstract available.

PMID:
6549095
17.

Chemical binding of folic acid and methotrexate to bovine fibrinogen.

Dyr JE, Slavík K, Vodrázka Z.

Thromb Res. 1983 Sep 1;31(5):737-46.

PMID:
6685928
18.
19.
20.

The chemotherapy of C3H mice bearing Gardner lymphosarcoma with bovine fibrinogen-methotrexate derivative.

Motycka K, Slavík K, Dyr JE, Balcarová A, Vodrázka Z.

Neoplasma. 1981;28(1):3-10.

PMID:
6895104
21.

Purification of thymidylate synthetase from enzyme-poor sources by affinity chromatography.

Slavík K, Slavíková V.

Methods Enzymol. 1980;66:709-23. No abstract available.

PMID:
6990200
22.

Distribution and pharmacokinetics of methotrexate in localized chemotherapy of solid Gardner's lymphosarcoma.

Slavíková V, Motycka K, Slavík K, Spacek P, Cihar R, Balcarová A.

Neoplasma. 1978;25(2):211-6.

PMID:
580447
23.

Treatment of solid Gardner lymphosarcoma with methotrexate sorbed on 2-hydroxyethylmethacrylate polymer in combination with leukovorin.

Motycka K, Slavík K, Balcarbová A, Cihar R, Spacek P, Kubín M.

Neoplasma. 1978;25(2):217-25.

PMID:
306074
24.

Purification of thymidylate synthetase from enzyme-poor sources by affinity chromatography.

Slavík K, Rode W, Slavíková V.

Biochemistry. 1976 Sep 21;15(19):4222-7.

PMID:
786369
25.

The effect of tetrahydropterins on oxidative phosphorylation in mitochondria of mice and rats exposed to X-rays or 60Co irradiation.

Vanícková V, Slavík K, Kraml J, Kocovská A.

J Nucl Biol Med. 1976 Apr-Jun;20(2):60-4. No abstract available.

PMID:
1011040
26.

Purification of thymidylate synthetase by means of affinity chromatography on tetrahydroamethopterin-aminoethyl-Sepharose.

Rode W, Zielińska ZM, Slavik K, Slavíková V.

Biochem Soc Trans. 1976;4(5):925-7. No abstract available.

PMID:
826438
27.

The purification of formiminotransferase and cyclodeaminase by combination of affinity chromatography and isoelectric focusing.

Slavik K, Zizkovský V, Slavíková V, Fort P.

Biochem Biophys Res Commun. 1974 Aug 19;59(4):1173-84. No abstract available.

PMID:
4472378
28.

Studies on the mechanism of antifolate induced inhibition on HeLa cell growth.

Pristoupilová K, Hermanová E, Slavík K.

Biochem Pharmacol. 1973 Aug 1;22(15):1937-42. No abstract available.

PMID:
4722461
29.
30.

[Antineoplastic agents. 44. Nuclear substituted beta-benzoyl-beta-brom(chlor)acryl acids and beta-4-methoxybenzoyl-alpha-bromacryl acid].

Semonský M, Zikán V, Vrba L, Jelínek V, Slavíková V, Slavík K, Kakác B.

Pharmazie. 1971 May;26(5):286-91. German. No abstract available.

PMID:
5563060
31.

The therapeutic effect of 2-amino-4-hydroxy-6-(1',2',3',4'-tetrahydroxybutyl)-5,6,7,8-tetrahydropteridine in x-irradiated mice.

Sonka J, Slavík K, Straková M, Cihar R.

Radiat Res. 1971 Mar;45(3):536-41. No abstract available.

PMID:
5574230
32.

Contribution to elucidation of biochemical action mechanism of Cytembena.

Slavíková V, Semonský M, Slavík K, Zikán V, Bloch A, Veselá H.

Neoplasma. 1971;18(5):455-7. No abstract available.

PMID:
5119518
33.

Cancerostatic agents. XXXVII. The effect of beta-aroly-beta-halogen acrylic acids on the tetrahydrofolic acid formylase.

Slavíková V, Semonský M, Slavík K, Zikán V, Volejníková J.

Biochem Pharmacol. 1969 Jun;18(6):1455-61. No abstract available.

PMID:
5799117
34.

Azahomoaminopterin, a new type of folic acid antimetabolite.

Slavík K, Slavíková V, Motycka K, Hermanová E, Soucek J, Tomsová Z, Spundová M, Nováková E.

Mol Pharmacol. 1969 Mar;5(2):137-47. No abstract available.

PMID:
4182381
35.

Alterations of some proteosynthetic reactions in the course of immunisation with heterologous proteins.

Horejsí J, Bednarík T, Holeysovská H, Hrubá A, Jezková Z, Jirásek A, Knesslová V, Nováková E, Paluska E, Slavík K.

Acta Univ Carol Med (Praha). 1969;15(5):469-93. No abstract available.

PMID:
4309411
36.

The treatment of experimental mouse hemoblastosis. VI.

Pristoupilová K, Soucek J, Motycka K, Slavík K.

Neoplasma. 1968;15(1):77-87. No abstract available.

PMID:
5689889
37.

Estimation of sensitivity of human tumors to cytostatics in vitro. I.

Andrysek O, Jandová A, Motycka K, Slavík K.

Neoplasma. 1968;15(1):59-69. No abstract available.

PMID:
5650630
38.

Inhibition of thymidylate synthetase by some analogs of tetrahydrofolic acid.

Slavik K, Zakrzewski SF.

Mol Pharmacol. 1967 Jul;3(4):370-7. No abstract available.

PMID:
6033635
39.

The effect of tetrahydrofolic acid on survival after whole body x-irradiation.

Sonka J, Slavík K, Pospísil J, Dienstbier Z.

J Nucl Biol Med. 1966 Jul-Sep;10(3):101-3. No abstract available.

PMID:
5978068
40.

Carcinostatic agents. XVI. Inhibition of purine biosynthesis and of tetrahydrofolic acid formylase by beta-4-methoxybenzoyl-beta-bromoacrylic acid.

Slavíková V, Semonský M, Slavík K, Volejníková J.

Biochem Pharmacol. 1966 Jun;15(6):763-8. No abstract available.

PMID:
5964255
41.

[On the mechanism of action of some new types of antimetabolites].

Slavík K.

Acta Univ Carol Med (Praha). 1965:Suppl 21:155+. Multiple languages. No abstract available.

PMID:
5880953
42.

The treatment of experimental mouse hemoblastosis. 3. Chemotherapy of the LaH VUFB leukemia with some 4-amino analogues of folic acid.

Soucek J, Sochman J, Motycka K, Novotná O, Slavík K.

Neoplasma. 1965;12(4):425-33. No abstract available.

PMID:
5854414
43.

ON THE MECHANISM OF ACTION OF SOME 4-AMINOANALOGUES OF FOLIC ACID.

SLAVIK K, SLAVIKOVA V, PRISTOUPILOVA K, SOUCEK J.

Acta Unio Int Contra Cancrum. 1964;20:1006-8. No abstract available.

PMID:
14274679
44.
45.

THE TREATMENT OF EXPERIMENTAL MOUSE HEMOBLASTOSIS. I. THE EFFECT OF SOME NEW FOLIC ACID ANTIMETABOLITES ON CELL TRANSPLANTED LEUKEMIA IN MICE OF THE AKR STRAIN.

MOTYCKA K, SOUCEK J, SLAVIK K, JIRASEK J, JIRASEK A.

Neoplasma. 1964;11:389-97. No abstract available.

PMID:
14200027
46.

ACTIVITY CHANGES OF SOME ENZYME SYSTEMS INTERFERING IN FOLIC ACID METABOLISM IN THE COURSE OF MOUSE LEUKAEMIA OF AKR-STRAIN.

SOUCEK J, MOTYCKA K, SLAVIK K.

Neoplasma. 1964;11:193-8. No abstract available.

PMID:
14163211
47.

The influence of some 4-amino analogues of tetrahydrofolate coenzymes of purine biosynthesis.

SLAVIKOVA V, SLAVIK K.

Biochim Biophys Acta. 1963 Jun 4;71:604-8. No abstract available.

PMID:
13989195
48.
49.

The difference in mechanism of action of aminopterin and some of its derivatives.

MOTYCKA K, SOCHMAN J, SLAVIKOVA V, SLAVIK K.

Physiol Bohemoslov. 1962;11:101-6. No abstract available.

PMID:
14476614
50.

The metabolism and coenzyme forms of folic acid.

SLAVIK K.

World Rev Nutr Diet. 1961;3:83-101. No abstract available.

PMID:
13989194

Supplemental Content

Loading ...
Support Center